Drug intelligence / Profile preview

BOS-356

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Topical

Overview

BOS-356 (also known as GSK 3008356) is a small molecule drug developed for the treatment of moderate to severe acne vulgaris. It acts as a selective inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1), an enzyme involved in triglyceride synthesis. By inhibiting DGAT1, BOS-356 aims to reduce sebum production and inflammation associated with acne. The drug was originally developed by GlaxoSmithKline and later by Boston Pharmaceuticals. Its primary route of administration is topical application, and it has completed phase I clinical trials for acne vulgaris[1][2][4][5].

Targets

DGAT1 (Diacylglycerol O-acyltransferase 1)

Beyond the preview

Go deeper on BOS-356.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOS-356.

Explore the full profile